Since the beginning of the coronavirus 2019 (COVID-19) pandemic, there has been enormous interest in understanding the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on people with HIV (PWH).
We used screening data and routine clinic records for intervention arm patients in the Simplified Algorithm for Treatment Eligibility (SLATE) trials to describe the prevalence of tuberculosis (TB) symptoms, diagnosis and treatment among people living with HIV (PLHIV), not on antiretroviral therapy (ART) and presenting at outpatient clinics in South Africa and Kenya. We compared the performance of the WHO four-symptom TB screening tool with a baseline Xpert test.
The Western Cape has released South Africa’s first local data, which finds that although people with these common illnesses are more vulnerable to COVID-19, they are less likely to die from the new coronavirus than many previously thought.
Background: Chronic respiratory illnesses and respiratory infections are common in HIV-positive populations. It seems reasonable that HIV-positive people experience more respiratory symptoms, such as coughing and breathlessness, than those who are HIV-negative.